{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 107 of 122', 'RWPC OUTCOMES AND TREATMENT / OBSERVATION', 'Negative RWPC', 'Release the subject if no symptoms are detected by the end of the 2-hour observation period.', 'Positive RWPC', 'Treatment of subjects with symptoms: Treat subjects with any symptoms elicited by the', 'RWPC per the accepted medical practices at the study site. Record all treatments', \"administered for allergic reactions in the subject's source documents and on case report\", 'forms.', '1. Assess the symptom severity and extend the monitoring period as appropriate. The', \"severity of the reaction will be determined based on the investigator's judgment.\", 'Definitions of allergic symptom severity are provided as a general guide in Table 2.', 'These definitions were developed consistent with the PRACTALL consensus report.', '2. Following the initial treatment, repeat treatments as needed, at the discretion of the', 'physician.', '3. Monitor vital signs (blood pressure, heart rate, temperature) at least every 15 minutes', 'until symptoms resolve, then 30 and 60 minutes after symptoms resolve, then hourly until', 'releasing the subject.', '4. Monitor pulse oximetry if laryngeal, lower respiratory, or cardiovascular symptoms are', 'present.', '5. Follow these guidelines for further observation based on symptom severity:', 'For severe symptoms, observe the subject for a minimum of 3 hours after the', 'symptoms resolve, either at the study site or an emergency facility, as appropriate.', 'Consider extended overnight observation if symptoms are protracted.', 'For moderate symptoms, observe the subject for a minimum of 2 hours after the', 'symptoms resolve, and longer if necessary.', 'For mild symptoms, observe the subject for a minimum of 2 hours or for 1 hour after', 'the symptoms resolve, whichever is longer.', '6. Do not release a subject with symptoms or with abnormal vital signs if changed from', 'baseline. As appropriate, arrange for continued observation at the study site, an', 'emergency facility, or an extended-stay (inpatient) unit. Record signs and symptoms that', \"changed from baseline in the subject's source documents.\"]['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 108 of 122', 'Table 2: Guide for Assessment of Allergic Reaction Symptom Severity by', 'Organ System', 'Organ System', 'Mild Symptoms', 'Moderate Symptoms', 'Severe Symptoms', 'Skin', 'Limited (few) or localized', 'Systemic hives (eg, numerous', 'Severe generalized', 'hives, swelling (eg, mild lip', 'or widespread hives), swelling', 'urticaria/angioedema/', 'edema), skin flushing', '(eg, significant lip or face', 'erythema', '(eg, few areas of faint', 'edema), pruritus causing', 'erythema) or pruritus (mild,', 'protracted scratching, more', 'eg, causing occasional', 'than a few areas of erythema', 'scratching)', 'or pronounced erythema', 'Respiratory', 'Rhinorrhea (eg, occasional', 'Throat tightness without', 'Laryngeal edema, throat', 'sniffling or sneezing), nasal', 'hoarseness, persistent cough,', 'tightness with hoarseness,', 'congestion, occasional', 'wheezing without dyspnea', 'wheezing with dyspnea,', 'cough, throat discomfort', 'stridor', 'Gastrointestinal', 'Mild abdominal discomfort', 'Persistent moderate', 'Severe abdominal', '(including mild nausea),', 'abdominal pain/cramping/', 'pain/cramping/repetitive', 'minor vomiting (typically a', 'nausea, more than a single', 'vomiting and/or diarrhea', 'single episode), and/or a', 'episode of vomiting and/or', 'single episode of diarrhea', 'diarrhea', 'Cardiovascular/', 'Subjective response (weak,', 'Moderate drop in blood', 'Cardiovascular collapse,', 'Neurologic', 'dizzy), or tachycardia', 'pressure and/or > 20% from', 'signs of impaired', 'baseline, or significant change', 'circulation (unconscious)', 'in mental status', 'POST-RWPC INSTRUCTIONS AND FOLLOW-UP', 'Before releasing the subject, study site staff should inform the subject and parent/caregiver of', 'the following:', '1. The subject may resume eating and drinking without restrictions 30 minutes after the', 'RWPC food is completely consumed. Subjects who complete the RWPC (regardless of', 'the outcome) will continue daily maintenance treatment with study product.', '2. Review the possibility of delayed allergy symptoms and provide guidance on how to', 'recognize anaphylaxis.', '3. Verify that they possess an epinephrine auto-injector with an appropriate dose and expiry', 'date before release, and review the instructions for administration of injectable', 'epinephrine.', '4. Provide study site staff contact information and procedures for after-hours emergencies.', '5. Instruct that the subject is to continue to avoid eating peanuts and foods known to contain', 'peanuts.', '6. Schedule a follow-up study appointment according to the protocol.', '7. Telephone the following day to inquire about post-RWPC adverse events, and assist', 'accordingly.']\n\n###\n\n", "completion": "END"}